Format

Send to

Choose Destination
Arch Pediatr Adolesc Med. 2001 Aug;155(8):915-20.

Hepatitis B vaccination practices in hospital newborn nurseries before and after changes in vaccination recommendations.

Author information

1
Division of General Pediatrics, University of Michigan, 300 N Ingalls Bldg, Room NI6E06, Ann Arbor, MI 48109-0456, USA. saclark@med.umich.edu

Abstract

BACKGROUND:

Routine use of hepatitis B vaccine for low-risk newborns was suspended on July 7, 1999, because of concern about the potential risk of thimerosal, a mercury-containing vaccine preservative. Reinstatement of the birth dose was recommended when a thimerosal-free vaccine became available.

OBJECTIVE:

To explore changes in hepatitis B vaccination practices for newborns related to the revised recommendations for low-risk infants (in this study, the terms newborn and infant are used interchangeably).

DESIGN:

A telephone survey of a random sample of 1000 US hospitals.

PARTICIPANTS:

Nurse managers, nursery directors, and staff nurses of the newborn nurseries.

MAIN OUTCOME MEASURES:

Nursery vaccination practices before and after July 7, 1999, and the availability and use of thimerosal-free vaccine.

RESULTS:

Interviews were conducted with 773 (87%) of 886 eligible hospitals. Before July 7, 1999, 78% of the hospitals reported vaccination practices that were consistent with recommendations at that time, although only 47% vaccinated all low-risk infants at birth. After July 7, 1999, almost all hospitals discontinued vaccination of low-risk infants, in accordance with the recommendation change; however, there was a 6-fold increase in the number of hospitals that were not vaccinating all high-risk infants. After the introduction of thimerosal-free vaccine, only 39% of the hospitals reported vaccinating all low-risk infants.

CONCLUSIONS:

Most hospital nurseries altered their newborn hepatitis B vaccination practices consistent with changes in national recommendations. However, unintended consequences included the failure of some hospitals to continue vaccinating all high-risk infants and the delay in reintroducing vaccination for low-risk newborns after the introduction of a thimerosal-free vaccine. Assessments of the appropriateness of this country's response to the threat of thimerosal in vaccines should consider these findings.

PMID:
11483119
DOI:
10.1001/archpedi.155.8.915
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center